University of Iowa Holden Comprehensive Cancer Center
200 Hawkins Dr., 7970 JPP Iowa City, IA 52242
About Network Member
Founded in 1980, the Holden Comprehensive Cancer Center at the University of Iowa has been an NCI comprehensive cancer center since 2001. The Center is dedicated to bringing the finest cancer care and research to Iowa and beyond.
Research at Holden is organized into four research programs: cancer genes and pathways, experimental therapeutics, free radical metabolism and imaging, and cancer epidemiology and population science. The Center promotes interactive cancer research, provides health care related to the prevention, detection, and treatment of cancer, and educates cancer professionals and the citizens of Iowa about cancer.
Holden is also organized around specific cancer types through its Multidisciplinary Oncology Groups which include a dozen multidisciplinary teams that are involved in both clinical care and research. The Center enrolls many patients in its active program of early phase clinical trials and also supports clinical and translational research done in collaboration with other cancer centers through efforts including the Iowa/Mayo Lymphoma SPORE, the National Clinical Trials Network and the Big Ten Cancer Research Consortium. Holden also is the only cancer center in the nation with a SPORE grant to study Neuroendocrine tumors.
Additional research is taking place through the efforts of multidisciplinary teams involved in cancer prevention, cancer and obesity, stem cell transplantation and molecular oncology. Holden has an active molecular oncology program that includes a Molecular Tumor Board and a Molecular Pathology team that is CLIA certified and CAP accredited and conducts multigene cancer hotspot mutation testing with next generation sequencing.
The Center supports 11 shared research resources that provide support to cancer investigators exploring molecular and cellular aspects of cancer, clinical trials and population studies. Holden has established prospective registries linked to biospecimens for select cancer types know as the Molecular Epidemiology Resources. Over 4000 subjects have been enrolled in these registries.
Website: Holden Comprehensive Cancer Center at the University of Iowa
A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)
A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363